Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients

doi:10.4239/wjd.v8.i3.112

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10823)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-6) series.

Item

Count

PDF

550

WORD

446

HTML

3972

Tables (1-6)

272

Sum=5240

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

810

Download

2009

Sum=2819

Publishing Process of This Article

Item

Count

Browse

1000

Download

1761

Sum=2761

Mar 15, 2017 (publication date) through Dec 27, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Diabetes. Mar 15, 2017; 8(3): 112-119
Published online Mar 15, 2017. doi: 10.4239/wjd.v8.i3.112

Table 3 Responders and non-responders before and after treatment with angiotensin converting enzyme inhibitor therapy

Patients	Urinary ACR at baseline¹	Urinary ACR at 6 mo	P-value	R² (%)	NR (%)
Overall (n = 252)	185.97 (55.66-222.20)	118.64 (96.24-146.26)	< 0.001	121	131
Micro-albumin (n = 170)	78.79 (71.30-87.07)	53.67 (44.46-64.79)	< 0.001	76	94
Macro-albumin (n = 82)	1068.7 (879.62–1298.28)	596.45 (451.60-787.68)	< 0.001	45	37

¹Median (IQR);

²A decline of > 30% in ACR value at 6 mo is considered as R. R: Responders; NR: Non-responders; ACR: Albumin/creatinine ratio.

Citation: Aggarwal N, Kare PK, Varshney P, Kalra OP, Madhu SV, Banerjee BD, Yadav A, Raizada A, Tripathi AK. Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients. World J Diabetes 2017; 8(3): 112-119
URL: https://www.wjgnet.com/1948-9358/full/v8/i3/112.htm
DOI: https://dx.doi.org/10.4239/wjd.v8.i3.112